chronic kidney disease - International Pharmaceutical Industry

HOME
CURRENT
FEATURES
EDITORIAL
ARCHIVES
ARCHIVED
ISSUES
EVENTS
COMPANY
PROFILES
A-D

E-M

N-S

T-Z
SPONSORED
ARTICLES
NEWS
EBOOKS

SCHOTT Pharma
PODCAST
Generic selectors

Exact matches only

Search in title

Search in content

Post Type Selectors

Current Edition

News

Positive results for GSK’s anaemia drug daprodustat

GlaxoSmithKline (GSK) has revealed positive data for its investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) daprodustat in patients...

9 November 2021 News anaemia | chronic kidney disease

Continue Reading →

News

New data at ESC Congress 2021 showcase AstraZeneca’s leading cardiovascular, renal and metabolic portfolio

At this year's European Society of Cardiology (ESC) Congress (27-30 August), AstraZeneca is sharing ...

25 August 2021 News AstraZeneca | Brilinta

Continue Reading →

News

US rejects AZ and FibroGen’s anaemia drug roxadustat

The US Food and Drug Administration (US) has handed AstraZeneca a complete response letter (CRL) regarding its anaemia drug roxadustat. AZ had submitted a new dru...

13 August 2021 News anaemia drug | AstraZeneca

Continue Reading →

News

AZ’s Forxiga gains EC, MHRA approvals for chronic kidney disease

AstraZeneca’s Forxiga (dapagliflozin), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, has been approved by the European Commission for the treatment of chronic ...